The next potential catalysts which could occur in Q4 are:
8-K filing (or filings) stating that the Governance issues noted in their previous 8-K dated 30 July 2013 have been resolved.
Announcement of the date of the pre-IND meeting concerning Hydrogel.
Announcement of permanent CFO assignment (either confirmation or replacement of Perry).
Announcement of results of the pre-IND meeting detailing the path to approval for Hydrogel (I consider that this is actually more likely to occur in Q1 2014 since meeting minutes will likely not have been signed-off until 30 days after the meeting itself)
Other than these, I think it's unlikely that any other significant drivers are forthcoming before Q1 2014. Since there was no mention of the possibility for listing to a National Exchange at the Aegis Conference I conclude that any such action has been tabled for now.
Q1 2014 should see progress on scaffold trials, permanent CEO assignment (confirmation or replacement of Astrue) and further progress on Hydrogel. Of course this is small-cap developmental biotech so we could get a bolt from the blue at any given moment. I'd keep my seat-belt buckled and my tray in the upright position at all times here.